Ginastera au bout de l'archet
Scientific Reports February 18, 2009 DOI: 10.1038/s41598-018-26656-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Two studies: open-label within-participant (psilocybin) and placebo-controlled double-blind crossover (MDMA) Peer reviewed |
|---|---|
| Sample size | 39 |
| Population | Healthy participants |
| Interventions | Psilocybin MDMA |
| Keywords | Piano |
| Citations | 38 |
| Key points | Both MDMA and psilocybin reduce rejection of unfair offers in the Ultimatum Game, with MDMA also increasing offers to others. |
Abstract
Disruptions in social decision-making are becoming evident in many psychiatric conditions. These are studied using paradigms investigating the psychological mechanisms underlying interpersonal interactions, such as the Ultimatum Game (UG). Rejection behaviour in the UG represents altruistic punishment - the costly punishment of norm violators - but the mechanisms underlying it require clarification. To investigate the psychopharmacology of UG behaviour, we carried out two studies with healthy participants, employing serotonergic agonists: psilocybin (open-label, within-participant design, N = 19) and 3,4-methylenedioxymethamphetamine (MDMA; placebo-controlled, double-blind, crossover design, N = 20). We found that both MDMA and psilocybin reduced rejection of unfair offers (odds ratio: 0.57 and 0.42, respectively). The reduction in rejection rate following MDMA was associated with increased prosociality (R2 = 0.26, p = 0.025). In the MDMA study, we investigated third-party decision-making and proposer behaviour. MDMA did not reduce rejection in the third-party condition, but produced an increase in the amount offered to others (Cohen's d = 0.82). We argue that these compounds altered participants' conceptualisation of 'social reward', placing more emphasis on the direct relationship with interacting partners. With these compounds showing efficacy in drug-assisted psychotherapy, these studies are an important step in the further characterisation of their psychological effects.
Citations in the library
Cited by 28
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation Journal of Psychopharmacology 2022
- Psychedelics, Sociality, and Human Evolution Frontiers in Psychology September 29, 2021
- Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA Neuroimage April 4, 2019
- Modulation of Social Cognition via Hallucinogens and “Entactogens” Frontiers in Psychiatry December 3, 2019
and 23 more in the library
Cites 22
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- The pharmacology of psilocybin Addiction Biology October 1, 2002
and 17 more in the library